open access
Diagnostic and therapeutic recommendations of the Polish Society of Hematology and Transfusion Medicine and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2016
Affiliations- Klinika Hematologii, Uniwersytet Medyczny w Łodzi, Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Łodzi, Kierownik: prof. dr hab. med. Tadeusz Robak, Łódź, Polska
- Samodzielna Pracownia Transplantologii Klinicznej, Uniwersytet Medyczny w Lublinie, Kierownik: prof. dr hab. med. Iwona Hus, Lublin, Polska
- Zakład Hematoonkologii Doświadczalnej, Uniwersytet Medyczny w Lublinie, Kierownik: prof. dr hab. med. Krzysztof Giannopoulos, Lublin, Polska
- Oddział Hematologiczny, Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli w Lublinie, Kierownik: prof. dr hab. med. Krzysztof Giannopoulos, Lublin, Polska
- Instytut Hematologii i Transfuzjologii, Warszawa. Dyrektor: prof. dr hab. n. med. Krzysztof Warzocha, Warszawa, Polska
- Zakład Immunologii Klinicznej, Uniwersytet Medyczny w Lublinie: Kierownik: prof. dr hab. Jacek Roliński, Lublin, Polska
- Zakład Hematologii Doświadczalnej, Uniwersytet Medyczny w Łodzi, Kierownik: prof. dr hab. med. Piotr Smolewski, Łódź, Polska
- Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Akademii Medycznej we Wrocławiu, Kierownik: prof. dr hab. Kazimierz Kuliczkowski, Wrocław, Polska
open access
Abstract
The management of patients with chronic lymphocytic leukaemia (CLL) is currently undergoing improvements, particularly because of novel therapies. Purine analogs based immuno-chemotherapy, especially fludarabine combined with cyclophosphamide and rituximab (FCR), is still the current standard of care for first line therapy in younger, fit patients. However, its use in older, co-morbid patients is limited, particularly due to high toxicity. In fit patients older than 65 years or/and with previous infections bendamustine and rituximab (BR) should be considered instead of FCR. Recently, in patients with relevant comorbidities chlorambucil and anti CD20 monoclonal antibodies (rituximab, obinutuzumab or ofatumumab) are recommended as the first-line treatment. In addition, in 2014, two novel agents targeting the B cell receptor (BCR) signaling pathway, ibrutinib and idelalisib, were approved for patients with 17p deletion and/or p53 mutations and in the relapsed situation because of high efficacy and a favorable toxicity. Subsequently, ibrutinib has been approved to treat CLL patients regardless of their treatment history. Thus far it is recommended to treat patients with these agents until progression or unacceptable toxicity. The BCL-2 antagonist venetoclax is another oral drug with very promising preliminary data in patients refractory to immunochemotherapy as well as patients harboring del 17p. In 2014, the PTHiT and PALG-CLL group defined guidelines for the diagnosis, prognosis and treatment of CLL. In this article, we present updated recommendations for therapy of CLL.
Abstract
The management of patients with chronic lymphocytic leukaemia (CLL) is currently undergoing improvements, particularly because of novel therapies. Purine analogs based immuno-chemotherapy, especially fludarabine combined with cyclophosphamide and rituximab (FCR), is still the current standard of care for first line therapy in younger, fit patients. However, its use in older, co-morbid patients is limited, particularly due to high toxicity. In fit patients older than 65 years or/and with previous infections bendamustine and rituximab (BR) should be considered instead of FCR. Recently, in patients with relevant comorbidities chlorambucil and anti CD20 monoclonal antibodies (rituximab, obinutuzumab or ofatumumab) are recommended as the first-line treatment. In addition, in 2014, two novel agents targeting the B cell receptor (BCR) signaling pathway, ibrutinib and idelalisib, were approved for patients with 17p deletion and/or p53 mutations and in the relapsed situation because of high efficacy and a favorable toxicity. Subsequently, ibrutinib has been approved to treat CLL patients regardless of their treatment history. Thus far it is recommended to treat patients with these agents until progression or unacceptable toxicity. The BCL-2 antagonist venetoclax is another oral drug with very promising preliminary data in patients refractory to immunochemotherapy as well as patients harboring del 17p. In 2014, the PTHiT and PALG-CLL group defined guidelines for the diagnosis, prognosis and treatment of CLL. In this article, we present updated recommendations for therapy of CLL.
Keywords
Chronic lymphocytic leukemia; Purine nucleoside analogs; Chlorambucil; Monoclonal antibodies; Idelalisib; Ibrutinib; Venetoclax
About this articleTitle
Diagnostic and therapeutic recommendations of the Polish Society of Hematology and Transfusion Medicine and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2016
Journal
Issue
Pages
169-183
Published online
2016-07-01
Page views
107
Article views/downloads
270
DOI
10.1016/j.achaem.2016.08.003
Bibliographic record
Acta Haematol Pol 2016;47(3):169-183.
Keywords
Chronic lymphocytic leukemia
Purine nucleoside analogs
Chlorambucil
Monoclonal antibodies
Idelalisib
Ibrutinib
Venetoclax
Authors
Tadeusz Robak
Iwona Hus
Krzysztof Giannopoulos
Jerzy Błoński
Krzysztof Jamroziak
Jacek Roliński
Piotr Smolewski
Dariusz Wołowiec